Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Simultaneous quantification of ramipril, glimepiride and metformin in human plasma by ultra-performance liquid chromatography – tandem mass spectrometry

Eman S. Elzanfaly, Sherif A. Abdel-Gawad.




Abstract

Ramipril (RAM), glimepiride (GLM) and metformin (MET) are recently formulated together for the treatment of diabetes and cardiovascular disorders. This work introduces a liquid chromatography–tandem mass spectrometric (LC-MS/MS) method for the simultaneous determination of the three drugs in human plasma after liquid-liquid extraction. This method made use of atorvastatin as internal standard (IS). Analytes were recovered from plasma by n-hexane: butanol (50:50%, v/v) and subsequently separated on Waters AcquityTM UPLC BEH shield RP-C18 column using methanol: water containing 0.1% formic acid (90: 10%, v/v) as a developing system. The calibration curves were linear (r2 > 0.99) over a range of 0.1 - 1000 ng/mL for RAM & GLM and 250 - 2000 ng/mL for MET. The intra-day and inter-day precisions were below 14.32% and the accuracy was all within ±15%. Moreover, other validation parameters for the proposed method like matrix effect, selectivity, recovery and stability were adopted. The proposed method can be applied for the sensitive and selective quantification of the analytes in bioavailability and pharmacokinetics studies.

Key words: Human plasma; liquid chromatography; ramipril, glimepiride, metformin






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.